PNT2258-02: A Pilot Phase II Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase of Trial: Phase II
Latest Information Update: 13 Jan 2017
At a glance
- Drugs Rosomidnar (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Biomarker; Therapeutic Use
- Sponsors ProNAi Therapeutics
- 19 Oct 2016 Status changed from active, no longer recruiting to completed.
- 06 Jun 2016 Results published in a ProNAi Therapeutics media release.
- 11 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History